GFPT1 Recombinant Rabbit mAb (S-4752-19)

Catalog Number: S0B60466 Application: WB, IHC-P Reactivity: Hu, Ms, Rt Conjugation: Unconjugated Brand: Starter

Price:

$100 USD

Size: 25μl 100μl 1ml

Quantity:

For shipping services or bulk orders, you may request a quotation.

Secure checkout with

View full details

Product Details

Product Specification

Host	Rabbit
Antigen	GFPT1
Synonyms	Glutamine--fructose-6-phosphate aminotransferase 1; D-fructose-6-phosphate amidotransferase 1; Glutamine:fructose-6-phosphate amidotransferase 1 (GFAT 1; GFAT1); Hexosephosphate aminotransferase 1; GFAT; GFPT
Immunogen	Synthetic Peptide
Location	Cytoplasm
Accession	Q06210
Clone Number	S-4752-19
Antibody Type	Recombinant mAb
Isotype	IgG
Application	WB, IHC-P
Reactivity	Hu, Ms, Rt
Positive Sample	HeLa, RD, K-562, 293T, Jurkat, MCF7, mouse testis, mouse placenta, rat placenta
Purification	Protein A
Concentration	0.5 mg/ml
Conjugation	Unconjugated
Physical Appearance	Liquid
Storage Buffer	PBS, 40% Glycerol, 0.05% BSA, 0.02% sodium azide
Stability & Storage	12 months from date of receipt / reconstitution, -20 °C as supplied

Dilution

application	dilution	species
WB	1:1000	Hu, Ms, Rt
IHC-P	1:500-1:2000	Hu, Ms, Rt

Background

GFPT1 (glutamine–fructose-6-phosphate transaminase 1) is the first rate-limiting enzyme in the hexosamine biosynthesis pathway (HBP), responsible for catalyzing the conversion of fructose-6-phosphate to glucosamine-6-phosphate, thereby controlling the glucose flux entering this pathway, and its encoding gene is located on human chromosome 2. This enzyme plays a dual role in both physiological and pathological processes: on one hand, its gene mutations have been identified as the cause of autosomal recessive congenital myasthenic syndrome type 12 (CMS12), with studies showing that muscle-specific GFPT1 deficiency leads to reduced UDP-N-acetylglucosamine (UDP-GlcNAc) synthesis, which subsequently affects protein O-GlcNAcylation and triggers endoplasmic reticulum stress and accumulation of misfolded proteins, ultimately resulting in structural abnormalities of the neuromuscular junction and muscle weakness; on the other hand, GFPT1 also plays important roles in various cancers, as it is upregulated in multiple tumors including pancreatic ductal adenocarcinoma, breast cancer, and hepatocellular carcinoma, and is significantly associated with poor patient prognosis and increased risk of lymph node metastasis, making it a potential prognostic biomarker, with the underlying mechanisms possibly involving promotion of metabolic adaptation in tumor cells, enhancement of translational activity, and cell cycle progression.

Picture

Western Blot

WB result of GFPT1 Recombinant Rabbit mAb
Primary antibody: GFPT1 Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: HeLa whole cell lysate 20 μg
Lane 2: RD whole cell lysate 20 μg
Lane 3: K-562 whole cell lysate 20 μg
Lane 4: 293T whole cell lysate 20 μg
Lane 5: JAR whole cell lysate 20 μg
Lane 6: Jurkat whole cell lysate 20 μg
Lane 7: MCF7 whole cell lysate 20 μg
Secondary antibody: Goat Anti-Rabbit IgG (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 77, 79 kDa
Observed MW: 77, 79 kDa
This blot was developed with high sensitivity substrate

WB result of GFPT1 Recombinant Rabbit mAb
Primary antibody: GFPT1 Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: mouse testis lysate 20 μg
Lane 2: mouse placenta lysate 20 μg
Secondary antibody: Goat Anti-Rabbit IgG (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 77, 79 kDa
Observed MW: 77 kDa
This blot was developed with high sensitivity substrate

WB result of GFPT1 Recombinant Rabbit mAb
Primary antibody: GFPT1 Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: rat placenta lysate 20 μg
Secondary antibody: Goat Anti-Rabbit IgG (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 77, 79 kDa
Observed MW: 77 kDa
This blot was developed with high sensitivity substrate

Immunohistochemistry

IHC shows positive staining in paraffin-embedded human kidney. Anti-GFPT1 antibody was used at 1/2000 dilution, followed by a HRP Polymer for Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

IHC shows positive staining in paraffin-embedded human testis. Anti-GFPT1 antibody was used at 1/2000 dilution, followed by a HRP Polymer for Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

IHC shows positive staining in paraffin-embedded human breast cancer. Anti-GFPT1 antibody was used at 1/2000 dilution, followed by a HRP Polymer for Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

IHC shows positive staining in paraffin-embedded human gastric cancer. Anti-GFPT1 antibody was used at 1/2000 dilution, followed by a HRP Polymer for Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

IHC shows positive staining in paraffin-embedded mouse testis. Anti-GFPT1 antibody was used at 1/500 dilution, followed by a HRP Polymer for Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.

IHC shows positive staining in paraffin-embedded rat testis. Anti-GFPT1 antibody was used at 1/500 dilution, followed by a HRP Polymer for Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.